3D Human Adipose-Derived Stem Cell Clusters as a Model for In Vitro Fibrosis.
Rajangam T., Park MH., Kim SH.
Laboratory Study, published in Tissue Eng Part C Methods (2016) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Tissue Eng Part C Methods (2016)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 27216608
- DOI
- 10.1089/ten.TEC.2016.0037
- Citations
- 12
Abstract (original English)
Excessive extracellular matrix (ECM) deposition is a cause of progressive fibrosis, which ultimately leads to progressive organ dysfunction. The lack of an in vitro fibrosis model and in vitro drug screening tools limits the development of effective antifibrotic drugs. The profibrotic cytokine transforming growth factor-β1 (TGF-β1), which is secreted by a variety of cells under continuous hypoxic condition, correlates strongly with tissue fibrosis and is largely responsible for the observed increases in ECM deposition in fibrotic diseases. In this study, we established an in vitro fibrosis model in which human adipose-derived stem cells (hASCs) secrete TGF-β1 by engineering three-dimensional cell masses (3DCMs) of hASCs on a maltose-binding protein-basic fibroblast growth factor (MBP-FGF2)-immobilized substrate. We found that the hypoxic microenvironment created in the interior of 3DCMs during the early stages of culture leads to activation and synthesis of TGF-β1. The gene expression of fibrosis-related molecules such as TGF-β1, α-smooth muscle actin (αSMA), and collagen type I was upregulated in 3DCMs. As culture time increased, overexpression of TGF-β1 led to differentiation of hASCs into activated myofibroblasts, which accumulate excessive collagen type I and are characterized by αSMA expression. Furthermore, immunofluorescence data verified the increase in collagen type I
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.